2022-502381-25-01Active, not recruitingPhase 1
A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers
Source: EU CTIS (euclinicaltrials.eu) · Last updated 3 Aug 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 97 (estimated)
- First submitted
- 22 Sept 2023
- Start date
- 15 Mar 2024
- Lead sponsor
- Novartis Pharma AG
- Diseases
- Colorectal cancer, Lung cancer, Kidney cancer, Head and neck cancer, Melanoma, Ovarian cancer, Triple-negative breast cancer, Mesothelioma
- EU CT number
- 2022-502381-25-01
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 97
- 7 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Technische Universität Dresden | Dresden | Germany | Active, not recruiting |
| Universitaetsklinikum Essen (AoR) | Essen | Germany | Active, not recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Active, not recruiting |
| Centre Leon Berard | Lyon | France | Completed |
| Institut Gustave Roussy | Villejuif | France | Completed |
| Fondazione IRCCS - Istituto Nazionale dei Tumori | Milan | Italy | Active, not recruiting |
| Azienda Ospedaliero - Universitaria di Modena | Modena | Italy | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.